Deborah Rathjen, PhD
CEO, Carina Biotech
Dr Rathjen is a highly experienced and respected leader in the biotechnology and pharmaceutical industries within Australia and internationally, and has achieved in excess of $800 million in deals including partnerships with Merck & Co., J&J, Abbott (AbbVie), Celgene, Nycomed (Takeda) and Merck KGaA. An immunologist by training, Dr Rathjen has extensive R&D experience in the areas of infection and immunity, inflammation, oncology, and neuroscience, covering multiple treatment modalities. As well as heading up Carina Biotech, Dr Rathjen is currently Executive Chair of US-headquartered Bioasis Technologies Inc. She is also a member of the Australian Medical Research Future Fund Advisory Board, the Million Minds Mental Health Research Mission Expert Panel, the Stem Cell Therapies Mission Expert Panel and the Federal Government’s Biomedical Translation Fund Committee.